Blood Clotting

News Blood Clotting

• Researchers reveal malaria's deadly grip

  Researchers at the University of Copenhagen, in collaboration with Seattle Biomedical Research Institute, the University of Oxford, NIMR Tanzania and Retrogenix LTD, have identified how malaria parasites growing inside red blood cells stick to the sides of blood vessels in severe cases of malaria. T more

• Agenix: Patent In Japan for Diagnostic Technology

  Agenix Limited  announced that Japan's Patent Office had granted a key patent covering the manufacturing process of its ThromboView® imaging agent for the detection of blood clots in humans. Agenix Chairman and Chief Executive Officer, Nicholas Weston said, "The granting of patent protection in Japa more

• CERMA creates spin-off company CERMAVEIN to commercialise steam vein sclerosis technology in varicose vein market

  Emerging medical technology company CERMA, specialized in the development of innovative and minimally invasive devices in phlebology and oncology, announced the creation of spin-off CERMAVEIN. CERMAVEIN was launched to expand commercialization of its proprietary Steam Vein Sclerosis (SVS™) technolog more

Publications Blood Clotting

• [News of the Week] Random Sample

  Adding to an often-used set of facial expression photographs of Caucasian adults, psychologists are now testing a new, multiethnic Child Affective Facial Expression set to see how well adults and children alike can identify children's facial expressions. And an expedition to study possible links bet more

• In This Issue [This Week in PNAS]

  Nanoparticles against atherosclerotic plaques Nanoparticles for atherosclerosis. Atherosclerosis is a leading cause of death in the United States, in part because the disease can go undetected for years or until plaques composed of cholesterol and fat-laden immune cells detach from the artery wall a more

• Rivaroxaban: a novel oral anticoagulant for the prevention and treatment of several thrombosis‐mediated conditions

  The development of rivaroxaban (XARELTO®) is an important new medical advance in the field of oral anticoagulation. Thrombosis‐mediated conditions constitute a major burden for patients, healthcare systems, and society. For more than 60 years, the prevention and treatment of these conditions have more

Market studies Blood Clotting

• Risk Evaluation and Mitigation Strategy (REMS) - Opioids, Erythropoesis-Stimulating Agents and Cancer Therapeutics are the Most Important Classes That Require REMS

  GBI Research's research, “Risk Evaluation and Mitigation Strategy (REMS) - Opioids, Erythropoesis-Stimulating Agents and Cancer Therapeutics are the Most Important Classes That Require REMS”, provides key data, information and analysis on the risk management and mitigation strategies, mandated by th more

• Protalex, Inc. (PRTX) - Financial and Strategic SWOT Analysis Review

  Protalex, Inc. (Protalex) is a publicly traded development stage bio pharmaceutical company, engaged in developing a novel, new class of therapeutic drugs for the treatment of autoimmune and inflammatory diseases. It principally focuses on developing a series of bio regulatory compounds based on the more

• PAION AG (PA8) - Financial and Strategic SWOT Analysis Review

  PAION AG (PAION) is a biopharmaceutical holding company. It develops and commercializes drugs for the hospital-based treatment of strokes and problems relating to the central nervous system (CNS), as well as other cardiovascular diseases. The company’s principal activity is advancement of drug candi more

Websites Blood Clotting